These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 27578767)

  • 41. Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms.
    Lugo-Radillo A; Cortes-Lopez JL
    J Psychoactive Drugs; 2021; 53(2):146-148. PubMed ID: 33225874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
    Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; Schmidt BL
    J Psychopharmacol; 2016 Dec; 30(12):1165-1180. PubMed ID: 27909164
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.
    Roseman L; Haijen E; Idialu-Ikato K; Kaelen M; Watts R; Carhart-Harris R
    J Psychopharmacol; 2019 Sep; 33(9):1076-1087. PubMed ID: 31294673
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers.
    Mathai DS; Hilbert S; Sepeda ND; Strickland JC; Griffiths RR; Garcia-Romeu A
    Psychedelic Med (New Rochelle); 2023 Dec; 1(4):241-252. PubMed ID: 38152462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
    Turton S; Nutt DJ; Carhart-Harris RL
    Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
    Griffiths R; Richards W; Johnson M; McCann U; Jesse R
    J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
    MacLean KA; Johnson MW; Griffiths RR
    J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Body mass index (BMI) does not predict responses to psilocybin.
    Spriggs MJ; Giribaldi B; Lyons T; Rosas FE; Kärtner LS; Buchborn T; Douglass HM; Roseman L; Timmermann C; Erritzoe D; Nutt DJ; Carhart-Harris RL
    J Psychopharmacol; 2023 Jan; 37(1):107-116. PubMed ID: 36373934
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hallucinogenic mushrooms in Denmark].
    Holm JW; Ebbehøj NE; Fjeldberg IA
    Ugeskr Laeger; 1997 Aug; 159(34):5116-8. PubMed ID: 9297322
    [No Abstract]   [Full Text] [Related]  

  • 51. From Mushrooms to Myolysis: A Case of Rhabdo in Psilocybin-Induced Mood and Psychotic Disorder.
    Suleiman M; Basu A; Belal S; Jacob T
    J Nerv Ment Dis; 2022 Aug; 210(8):638-639. PubMed ID: 35900779
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches.
    Garcia-Romeu A; Barrett FS; Carbonaro TM; Johnson MW; Griffiths RR
    J Psychopharmacol; 2021 Apr; 35(4):353-361. PubMed ID: 33611977
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
    Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX
    Eur Neuropsychopharmacol; 2016 Apr; 26(4):756-66. PubMed ID: 26875114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Health Benefits and Positive Acute Effects of Psilocybin Consumption: A Quantitative Textual Analysis of User Self-Reported Data.
    Bienemann B; Barbosa AR; Cruz LVMD; Multedo M; Mograbi D
    J Psychoactive Drugs; 2024; 56(3):324-332. PubMed ID: 37348116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Consumption of psilocybin-containing hallucinogenic mushrooms by young people].
    Lassen JF; Lassen NF; Skov J
    Ugeskr Laeger; 1992 Sep; 154(39):2678-81. PubMed ID: 1413197
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Finding the self by losing the self: Neural correlates of ego-dissolution under psilocybin.
    Lebedev AV; Lövdén M; Rosenthal G; Feilding A; Nutt DJ; Carhart-Harris RL
    Hum Brain Mapp; 2015 Aug; 36(8):3137-53. PubMed ID: 26010878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ethnobotany of psilocybin mushrooms, especially Psilocybe cubensis.
    Badham ER
    J Ethnopharmacol; 1984 Apr; 10(2):249-54. PubMed ID: 6539409
    [No Abstract]   [Full Text] [Related]  

  • 58. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
    Burdick BV; Adinoff B
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of hallucinogens in Slovakia: Does it differ from global trends?
    Lukačovič M; Masaryk R
    Int J Drug Policy; 2021 Dec; 98():103385. PubMed ID: 34364200
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.